Article
Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report.
BMC pulmonary medicine - 27 Sept 2024
Sun Cheng, Liang Zhike, Yan Zhiyun, Feng Yawen, Tang Wanna, Wei Shuquan, Zhong Weinong, Zhao Ziwen, Li Yujun
Abstract excerpt
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a life-threatening condition frequently encountered in critically ill patients, including those with advanced non-small cell lung cancer (NSCLC). Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown promise as a first-line treatment for NSCLC with classical EGFR mutations. However, its efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
